- Trial phase
- Phase 3
- Time to market
- Several years away, if successful. Phase 3 MMN trial won't complete final data collection until December 2029. A potential BLA submission would follow positive Phase 3 data, likely no earlier than 2027-2028.
- Why 6/10
- The next hard catalyst is the estimated primary completion of the Phase 3 MMN trial (NCT06742190) in September 2026, a pivotal topline readout due imminently. While empasiprubart is a meaningful pipeline asset, argenx's valuation (~$60B market cap) is overwhelmingly driven by its approved Vyvgart franchise, not this experimental drug, capping the share-price impact.
Watch for Phase 3 topline MMN data (estimated primary completion Sep 2026). Positive data could add a new pipeline pillar, but empasiprubart is not the primary value driver at argenx, Vyvgart's commercial trajectory and the myositis readout for efgartigimod are larger stock-moving events. A Phase 2 dermatomyositis readout is also expected by November 2026.
Price Chart
Executive Summary
Empasiprubart is an investigational complement-targeting antibody being developed by argenx SE (ARGX) for two rare autoimmune indications: multifocal motor neuropathy (MMN) in Phase 3 and dermatomyositis in Phase 2. The nearer-term catalyst is the estimated primary completion of the Phase 3 MMN trial (NCT06742190) around September 2026, with results pitting empasiprubart head-to-head against IVIg. However, argenx is a large, profitable biotech with $1.5B/quarter in Vyvgart sales, making empasiprubart one pipeline asset among several. The drug has no approved status, no PDUFA date, and limited public data on mechanism or prior efficacy results.
How It Works
Empasiprubart is an antibody designed to block the complement system, a part of the immune system that can mistakenly attack healthy cells in autoimmune diseases. By inhibiting a specific complement protein, it aims to reduce nerve and muscle damage in conditions like multifocal motor neuropathy and dermatomyositis. This is a different mechanism than argenx's approved drug Vyvgart, which blocks FcRn.
Trial Status
Empasiprubart has two active trials: a Phase 3 study (NCT06742190) comparing it against IVIg in ~154 patients with multifocal motor neuropathy (started Dec 2024, estimated primary completion Sep 2026, final completion Dec 2029), and a Phase 2 study (NCT06284954) in ~3 patients with dermatomyositis (started Aug 2024, estimated primary completion Nov 2026). Both trials are listed as 'active, not recruiting' with no results posted yet.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 MMN topline readout, estimated primary completion Sep 2026 (imminent)
- Phase 2 dermatomyositis topline readout, estimated primary completion Nov 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
argenx SE Press Release ARGX ·Originating report